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short stature. An improvement of well-being was reported 
by half of the parents of treated and untreated children. 
Fears about GH treatment disappeared almost completely. 
 Conclusion: The perspective of GH treatment induced major 
adult height expectations. In treated children, the physical 
effects of GH treatment became obvious, teasing because of 
short stature decreased and initial concerns about short 
stature and GH therapy decreased. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Children born small for gestational age (SGA) remain 
short of stature in up to 10–15% of cases, and present to 
varying degrees with difficulties in neurological, senso-
ry-motor and cognitive development  [1–5] . Several short-
term and long-term studies have shown a beneficial effect 
of growth hormone (GH) therapy on growth in the ma-
jority of these short SGA children  [6–9] .
 To our knowledge, few data are available on how young 
children and their parents perceive short stature and the 
growth-promoting effects of GH treatment, or whether 
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 Abstract 
 Background/Aims: Few data are available about parental 
concerns and psychosocial functioning of young children 
born small for gestational age (SGA) treated with growth 
hormone (GH). The present study focused on the perception 
of short stature and the concerns and expectations of the 
parents regarding GH treatment.  Methods: Forty prepuber-
tal short SGA children, randomized into a GH-treated and a 
GH-untreated group, and their parents were evaluated by a 
questionnaire and a semi-structured interview at start and 
after 2 years of follow-up .  Results: Before start, 85% of the 
parents were concerned about short stature, 76% expected 
an increase in adult height of  6 10 cm and 81% expected a 
positive impact on well-being. Half of the parents expressed 
fears regarding GH treatment. After 2 years, more parents of 
treated children reported obvious growth and physical 
changes, and fewer parents reported teasing because of 
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the children tolerate this treatment well or not  [10–12] . 
Moreover, findings in SGA children might be different 
from other conditions associated with short stature, giv-
en the associated health and developmental problems in 
SGA children  [13, 14] and the potential association with 
the educational and socioeconomic status of the parents 
 [3, 15–17] . We hypothesized that these concerns and ex-
pectations might be influenced by the presence of health 
and developmental problems in the child as well as by the 
mother’s height, weight, educational level and socioeco-
nomic status. 
 In the present study we evaluated in young short SGA 
children the parents’ and children’s perception of short 
stature, their perception of the effects of GH treatment on 
growth, physical appearance and psychosocial function-
ing, the parental concerns and expectations regarding 
GH treatment, and the psychological tolerance of GH 
treatment by the child. In addition, potential associations 
were investigated between parental expectations and 
concerns regarding GH treatment on the one hand and 
the auxological and clinical characteristics of the child 
and the clinical, demographic and socioeconomic status 
of the mother on the other. 
 Patients and Methods 
 Patients 
 Over an inclusion period of 1.5 years, 40 prepubertal children 
(18 boys), from among the SGA children consulting for short stat-
ure in the paediatric departments of 10 Belgian and 1 Luxem-
bourg hospital centres, were recruited for this study. The inclu-
sion criteria were birth weight and/or length below –2 SD for ges-
tational age  [18] , chronological age between 3 and 8 years, current 
height below –2.5 SD  [19] and a height velocity standard deviation 
scores (SDS) below +1.0 SD during the last 6 to 18 months  [20] . 
The exclusion criteria were gestational age below 34 weeks, endo-
crine disease including GH deficiency, bone disease, severe 
chronic disease, Turner, Noonan or Down syndrome or other ge-
netically confirmed syndromes, chromosomal abnormalities, 
current or previous irradiation therapy, current or previous (up 
to 18 months before inclusion) treatment with glucocorticoids 
and severe mental retardation (IQ  ^  50).
 Children were randomized into a treated (TR) group (n = 20) 
and an untreated group (UTR) group (n = 20) taking into account 
the following parameters: gender, chronological age, weight SDS 
and study centre. Based on a 0.8 power to detect a significant dif-
ference (p = 0.05), 20 subjects in each group were required, assum-
ing a difference of 2 cm/year in height velocity and a standard 
deviation of 2.2 cm/year. For ethical reasons the untreated group 
did not receive daily placebo injections but underwent the same 
investigations. The treated children received biosynthetic human 
GH (Genotonorm  , Pfizer Inc, Belgium) for 2 years in a dosage of 
0.066 mg/kg   day. One treated patient dropped out of the study 
after 1 year because of family problems. Written informed con-
sent was obtained from the parents before enrolment in the study. 
The ethical review board of each participating centre approved 
the study protocol. 
 Methods 
 The standard auxological assessment consisted of height, 
weight and head circumference measurements every 6 months by 
the same clinical monitor (M.T.). Height, weight, BMI and head 
circumference SDS were calculated using the British references 
 [19] . The psychological evaluation was performed at the start of 
the study (T0), without parents and child knowing whether GH 
therapy was going to be started immediately or after 2 years, and 
after 2 years of follow-up (T2). A questionnaire for the parents and 
a semi-structured interview for the child and the parents were 
developed for the study.
 From the questionnaire completed by the parents at T0, gen-
eral information about the child’s clinical and mother’s educa-
tional, professional and socioeconomic status was obtained. Par-
ents were asked which adult height they expected for their child 
with and without GH treatment, and which expectations and 
fears they had with respect to GH treatment. The parental expec-
tations and fears regarding GH treatment were evaluated on the 
basis of a 4-point Likert scale (not at all, somewhat, a lot, very 
much). The expectations concerned, in addition to the growth-
promoting effect of GH treatment, a potential positive or negative 
effect on how the child feels (psychological well-being). The fears 
referred to difficulties to maintain the treatment for the child and 
for the parents, difficulties regarding the administration of the 
injections (preparation, pain, daily constraint, duration) as well 
as fear of side effects. 
 On the basis of a semi-structured interview with the parents 
and the child (where possible, given the young age and delay in 
cognitive development in some cases) the following parameters 
were assessed: the perception of short stature and difficulties 
experienced with it; the previous and current health and devel-
opmental problems and psychosocial functioning (in particular 
how the child feels and teasing by peers). The same parameters 
were evaluated at T0 and at T2 in the TR as well as in the UTR 
group, using equivalent adapted questions for the UTR group 
(regarding growth, physical changes and how the child feels). In 
addition, parents were asked whether they observed changes 
with respect to the above-mentioned parameters after 2 years 
compared to the start. The children were asked whether being 
small was annoying and why, on the basis of a 4-point Likert 
scale (from not at all to very much).  After 2 years, the perception 
of GH treatment was evaluated in both parents and children. 
Parents were questioned about the difficulties to maintain the 
treatment, difficulties regarding the administration of the injec-
tions (preparation, pain, daily constraints, long duration of 
treatment), fear of side effects and their compliance to the GH 
treatment. The children were asked whether the injections were 
difficult to maintain, painful or annoying or whether they be-
came a habit, on the basis of a 4-point Likert scale (from not at 
all to very much.)
 The perception of the effects of GH treatment on linear growth 
and other physical changes (less baby-face, looking more mature 
or older) were assessed in parents and children with the aid of a 
photograph of the child taken at each evaluation. Satisfaction 
with the effect of GH treatment was investigated by asking the 
parents to give a satisfaction score on the basis of a 7-point Likert 
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scale (from not satisfied at all to very satisfied). The compliance 
to GH treatment was evaluated by asking the parents how fre-
quently they had forgotten to give the injections on a 4-point Lik-
ert scale (from never to often). Parents who answered that they 
had forgotten to give the injections were questioned about the real 
frequency (how many times for the past year). 
 For each of the responses of both children and parents, any 
differences between treated and untreated children were investi-
gated at T0 as well as at T2. Answers to some items of the interview 
are lacking for some children and parents mainly because of the 
young age of the child.
 In addition, the influence of the child’s clinical characteristics 
(gender, preschoolers or school-age, presence of minor dysmor-
phic features, current health problems, developmental delay and 
need of specialized care at start of the study) on the auxological 
parameters were examined at T0 and at T2. Potential associa-
tions with the auxological parameters of the child were studied 
by dividing the following variables into tertiles: birth weight 
SDS, height SDS, BMI SDS and head circumference SDS at 
start.
 In order to study potential maternal influences, the mothers’ 
auxological and demographic characteristics at start of the study 
were taken into account. The mothers’ ages, heights and BMIs 
were divided into tertiles. The auxological data of 2 adoptive and 
2 foster mothers were not included in the analysis. The mothers’ 
demographic characteristics comprised educational status, eval-
uated according to 3 levels: low, medium, high; professional sta-
tus, covering working (5 categories) or not working situation (2 
categories); and socioeconomic status or financial situation at 
home, evaluated according to 3 levels (difficult, short of cash, no 
problem). 
 Potential associations were investigated between initial paren-
tal concerns about short stature, initial fears with respect to GH 
treatment and parents’ expectations regarding the effects of GH 
treatment and the child’s and mother’s auxological and clinical 
characteristics at start. 
 Statistical Analysis 
 Clinical and auxological results are expressed as means  8 SD, 
interview data as absolute numbers and percentages. Differences 
of continuous variables between subgroups were evaluated by 
Student’s unpaired t test or by the Mann-Whitney U test as ap-
propriate, and differences of categorical variables by the   2 test or 
by Fisher’s exact test as appropriate at T0 and at T2. Changes in 
auxological results were evaluated by Student’s paired t test, and 
changes in interview data by the   2 test or by Fisher’s exact test as 
appropriate. The level of significance of difference was set at p  ! 
0.05. Statistical analysis was performed using SPSS software (ver-
sion 12, SPSS Inc., USA). 
 Results 
 Auxological, Clinical and Demographic 
Characteristics of the Children 
 Table 1 shows the auxological data at T0 and at T2. 
Chronological ages at the start of the study ranged be-
tween 3.2 and 7.8 years. At T0 there were no differences 
in the auxological parameters between the TR and the 
UTR patients. After 2 years of GH therapy, the patients 
of the TR group were significantly taller (–1.9  8 0.7 SDS 
vs. –3.1  8 0.9 SDS; p  ! 0.001) and heavier (–2.3  8 1.2 
SDS vs. –3.7  8 1.5 SDS; p  ! 0.01), and had a larger head 
circumference (–2.0  8 1.4 SDS vs. –2.8  8 1.6 SDS; p  ! 
0.05). None of the patients entered puberty during the 
study period.
 The clinical data of the children are presented in  ta-
ble 2 . Eight (20%) children presented minor dysmorphic 
features, suggestive of Silver-Russell syndrome (n = 3),
Total group
(n = 40)
TR group
(n = 20)
UTR group
(n = 20*)
p
Neonatal data
Birth weight (SDS) –2.780.8 –2.780.9 –2.680.8 ns
Gestational age, weeks 37.781.9 37.382.1 38.281.6 ns
Data at start
Age, years 5.381.5 5.581.6 5.181.3 ns
Height (SDS) –3.380.8 –3.380.6 –3.280.9 ns
Weight (SDS) –3.881.4 –3.881.3 –3.981.4 ns
BMI (SDS) –1.981.3 –1.781.1 –2.081.5 ns
Head circumference (SDS) –2.781.5 –2.781.4 –2.881.6 ns
Data after 2 years
Height (SDS) –2.480.9 –1.980.7 –3.180.9 <0.001
Weight (SDS) –3.081.5 –2.381.2 –3.781.5 <0.01
BMI (SDS) –1.781.3 –1.581.1 –2.081.5 ns
Head circumference (SDS) –2.481.5 –2.081.4 –2.881.5 <0.05
Values are means 8 SD. *n = 19 for data after 2 years.
Table 1. Auxological data of the
GH-treated (TR) and untreated (UTR) 
children at birth and at start of the
study (T0) and after 2 years (T2)
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3- M syndrome (n = 1), Renpenning syndrome (n = 1) or 
another non-specified genetic syndrome (n = 3). Chil-
dren with dysmorphic features had a lower birth weight 
(–3.5  8 1.1 SDS vs. –2.5  8 0.6 SDS; p  ! 0.005). At T0, 
parents reported chronic health problems in 9/39 (23%) 
 of the children, mainly recurrent respiratory, digestive 
and orthopaedic problems. Half of the SGA children had 
developmental problems, defined as a delay in learning to 
walk and talk and in toilet training. Birth weight was low-
er in these children (–3.0  8 1.1 SDS vs. –2.3  8 0.4 SDS; 
p  ! 0.005). Twelve of the 36 (30%) children needed spe-
cialized care (physical, speech or psychomotor therapy) 
at T0. No differences were observed between the TR and 
UTR group.
 At start of the study, some auxological parameters 
were related to the clinical characteristics. Children with 
dysmorphic features had a lower height (–3.8  8 1.2 SDS 
vs. –3.1  8 0.6 SDS; p  ! 0.05) and BMI (–3.0  8 1.7 SDS 
vs. –1.6  8 1.1 SDS; p  ! 0.05). Children with developmen-
tal problems had a lower BMI (–2.4  8 1.3 SDS vs. –1.3  8 
1.2 SDS; p  ! 0.05) and smaller head circumference (–3.7 
 8 1.5 SDS vs. –1.8  8 1.1 SDS; p  ! 0.001). Children who 
needed specialized care had a smaller head circumfer-
ence (–3.6  8 1.7 SDS vs. –2.4  8 1.4 SDS; p  ! 0.05).
 Auxological and Demographic Characteristics of the 
Mothers 
 The auxological and demographic data of the mothers 
of the studied children are shown in  table 3 . The mothers’ 
mean height was significantly below the population mean 
(157.1  8 5.7 cm; –1.1  8 1.0 SDS). Five women were small-
er than the 3rd percentile. Three women were overweight 
(BMI  1 25 kg/m 2 ), 1 was obese (BMI  1 30 kg/m 2 ), and 5 
women were underweight (BMI  ! 18.5 kg/m 2 ). The moth-
ers’ educational status (low, medium, high) was evenly 
Total group TR group UTR group 
At start
Dysmorphic features 8/40 (20) 3/20 (15) 5/20 (25)
Chronic health problems 9/39 (23) 4/19 (21) 5/20 (25)
Developmental problems 18/36 (50) 8/18 (47) 10/18 (53)
Specialized care needed 12/36 (30) 5/18 (28) 7/18 (39)
After 2 years
Developmental problems 14/39 (36) 7/19 (37) 7/20 (35)
Specialized care needed 14/39 (36) 7/19 (37) 7/20 (35)
Results are expressed as the number of children with the respective problem. Figures 
in parentheses are percentages.
Table 2. Clinical characteristics of the 
GH-treated (TR) and untreated (UTR) 
children at start (T0) and after 2 years 
(T2)
Table 3. Auxological and demographic characteristics of the 
mothers of GH-treated (TR) and untreated (UTR) children
All patients TR Group UTR Group
Mothers’ auxological characteristics1
Age, years 32.783.7 32.983.7 32.483.8
Height, cm 157.185.7 155.187.6 159.185.0
Weight, kg 52.189.3 49.787.6 54.4810.4
BMI, kg/m2 21.083.2 20.782.9 21.483.5
Mothers’ demographic characteristics2
Educational status
Low 14/40 (35) 7/20 (35) 7/20 (35)
Medium 13/40 (32.5) 7/20 (35) 6/20 (30)
High 13/40 (32.5) 6/20 (30) 7/20 (35)
Professional status
Working 24/40 (60) 11/20 (55) 13/20 (65)
Without work 16/40 (40) 9/20 (45) 7/20 (35)
Working categories:
1 employee 13 6 7
2 independent 2 2 0
3 employer 0 0 0
4 functionary 2 0 2
5 labourer 6 3 3
Without work:
1 housewife 13 7 6
2 unemployed 3 2 1
Financial situation
Difficult 2/40 (5) 1/20 (5) 1/20 (5)
Short of cash 8/40 (20) 3/20 (15) 5/20 (25)
No problem 30/40 (75) 16/20 (80) 14/20 (70)
1 Data of 36 mothers; data of biological mothers are missing 
for 2 foster and 2 adopted children. Values are means 8 SD. 
2 Data of 40 mothers; characteristics of adoptive and foster 
mothers are included. Figures in parentheses are percentages.
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distributed. Twenty-four (60%) mothers were working 
and 30 (75%) reported that they did not have any finan-
cial problems. No differences were found between moth-
ers of treated and untreated children.
 Perception of and Concerns about Short Stature at 
Start of the Study 
 Thirty-three (85%) parents were concerned about the 
short stature of their child, and according to 12 (31%) par-
ents their child was teased because of short stature. Four-
teen (38%) children reported being annoyed by their stat-
ure. Parental concerns about the short stature of the child 
were not related to any of the auxological or clinical char-
acteristics of the child, nor to the auxological or demo-
graphic characteristics of the mothers ( Table 4 ). 
 Expectations and Fears Regarding GH Therapy at 
Start of the Study 
 Before the start of GH treatment, 30 (76%) parents ex-
pected a gain in adult height of at least 10 cm; 11 (27%) of 
them expected even 18 cm or more. Median expected 
height gain was 12 cm (range: 0–40 cm) and was similar 
for boys and girls. For boys, parents expected an adult 
height of 169.9  8 6.1 cm with and of 156.9  8 8.5 cm 
without GH treatment and for girls an adult height of 
160.1  8 6.9 cm with and of 146.1  8 13.0 cm without GH 
treatment. Thirty-two (80%) parents expected an im-
provement of the child’s psychological well-being.
 Expectations of an adult height gain of more than 18 
cm were more frequently observed in parents of children 
with a lower birth weight (60% in children with the low-
est birth weight SDS vs. 9% in children with the highest 
birth weight SDS tertile; p  ! 0.05), and in parents of chil-
dren who received specialized care (55% when the child 
received specialized care vs. 24% when the child did not 
receive specialized care; p  ! 0.05). 
 The evaluation of fears regarding GH treatment re-
vealed that painfulness of injections and potential side 
effects due to GH treatment were the most frequently re-
ported constraints (18 and 20 parents, respectively). Par-
ents were more frequently concerned about side effects in 
girls (73% of the parents of girls versus 18% of parents of 
boys; p  ! 0.005) and in children with a higher height at 
start (82% of the parents of children with the highest 
Table 4. Perception of short stature (SS), growth and psychosocial functioning at start and after 2 years in GH-
treated (TR) and untreated (UTR) children
Total group TR group UTR group p
Perception of and concerns about SS and well-being at start
According to parents
Concerned about SS 33/39 (85) 19/19 (100) 14/20 (70) <0.05
Child teased by peers because of SS 12/39 (31) 7/20 (35) 5/19 (26) ns
According to the child
Annoyed by SS 14/37 (38) 5/19 (26) 9/18 (50) ns
Perception of changes in height and physical appearance after 2 years
According to parents
Concerns about SS 14/39 (36) 5/19 (26) 9/20 (45) ns
Child has grown 29/36 (80) 17/17 (100) 12/19 (31) <0.05
Child has physically changed 22/30 (73) 15/16 (94) 7/14 (50) <0.05
Child has become stronger 16/38 (42) 11/18 (61) 5/20 (25) <0.05
According to the child
Annoyed by SS 14/36 (39) 2/16 (12) 12/20 (60) <0.05
Obviously grown 19/34 (56) 17/17 (100) 12/17 (71) <0.05
Perception of changes in psychosocial functioning after 2 years
According to parents
Child teased because of SS 11/39 (28) 2/19 (10) 9/20 (45) <0.05
Child feels better 20/39 (51) 9/19 (47) 11/20 (55) ns
Results are expressed as the number of positive answers for each item. Figures in parentheses are percent-
ages.
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height SDS tertile vs. 36% of the parents of children with 
the lowest height SDS tertile; p  ! 0.05). Mothers with a 
higher socioeconomic status (SES) were more concerned 
about side effects (57% of the mothers with the highest 
SES vs. 22% with the lowest SES; p = 0.05) and painful-
ness of injections (50% of the mothers with the highest 
SES vs. 30% with the lowest SES; p  ! 0.05).
 Perception of Changes in Height, Physical Appearance 
and Psychosocial Functioning after 2 Years 
 Five (26%) parents of GH-treated children and 9 (45%) 
parents of untreated children were still concerned about 
the stature of their child. Changes in body size and phys-
ical appearance were more obvious for parents of treated 
children than for parents of untreated children, as evalu-
ated by the following parameters: obvious growth (100 vs. 
31%; p  ! 0.05), physical changes (94 vs. 50%; p  ! 0.05) and 
increased strength (61 vs. 25%; p  ! 0.05). After 2 years, a 
smaller number of treated children reported being still 
annoyed by stature (12 vs. 60% in the untreated group,
p  ! 0.05).  All GH-treated children reported that they had 
obviously grown (100 vs. 71% of the untreated children, 
p  ! 0.05). 
 With respect to psychosocial functioning, a smaller 
number of parents reported teasing by peers after 2 years 
when the child was treated (10 vs. 45%; p  ! 0.05). Regard-
ing changes in psychological well-being, half of the par-
ents of the treated (47%) and of the untreated children 
(55%) reported an increase in self-confidence and/or im-
provement of self-esteem ( table 4 ).
 Tolerance of GH Treatment  
 After 2 years of GH treatment, only 2 of 19 (10%) par-
ents reported fears of side effects compared to 9/20 (49%) 
before the start of GH treatment. Regarding the accep-
tance of GH treatment, all parents thought that the injec-
tions had become a habit for the child, and none of them 
thought that the injections were still painful after 2 years, 
in contrast to 45% of the parents reporting that the injec-
tions had been painful for their child in the beginning, 
i.e. the first weeks. After 2 years, the injections had be-
come a habit for 83% of the children, but 59% of the chil-
dren still found the injections somewhat painful. Parent’s 
reporting on how the child accepted GH treatment was 
not significantly different for preschool children com-
pared to school-age children. 
 Regarding the compliance with GH treatment after 2 
years, 4 of the 19 (21%) parents of treated children report-
ed that they never forgot to give the injections, 13/19 
(68%) reported that they rarely forgot the injections and 
none of the parents reported that they often forgot the 
injections. All parents gave a very high satisfaction score 
(6 or 7) with respect to GH treatment. 
 Discussion 
 This study describes the concerns about short stature 
and the concerns and expectations about GH treatment, 
as well as the perception of the physical and psychological 
effects of GH treatment in young short SGA children, on 
the basis of a questionnaire for the parents and an exten-
sive interview with the parents and the child.
 A first interesting finding is that, although consulting 
a paediatric endocrinologist and participating in a 
growth-promoting study, 15% of the parents were not 
concerned about the short stature of their child. Taking 
into account that, at start of the study, half of the children 
had developmental problems and one quarter suffered 
from chronic health problems, we cannot exclude that 
these problems resulted in contacting a physician who 
drew attention to the short stature. It is, however, note-
worthy that parents’ initial concerns about the short stat-
ure of their child were not influenced by the health or 
developmental status of the child. Another explanation 
could be that not all parents were aware of the limited 
adult height expectations for their child before referral. 
Furthermore, only one third of the children themselves 
worried about their short stature. In a previous study in 
children with Turner syndrome, we observed that chil-
dren younger than 6 years did not perceive their short 
stature as a problem  [12] . Moreover, the social impact of 
short stature at this young age is limited and previous 
studies in short-stature children even reported some pos-
itive social experiences in early childhood  [21, 22] .
 Even though concerns about short stature were not 
present in all parents, expectations of increased adult 
height were high. Three quarters of the parents expected 
an adult height gain of 10 cm or more, and 1 quarter of 
the parents 18 cm or more. Unrealistic future height ex-
pectations at the start of GH therapy have been reported 
previously in patients with Turner syndrome and their 
parents  [12, 23] . In our study, parental adult height expec-
tations were influenced by some of the auxological char-
acteristics of the child: a low birth weight and a small 
head circumference, linked to the need of specialized 
care in our population, were associated with higher adult 
height expectations. The confrontation with develop-
mental problems in the child from early childhood could 
increase the awareness for the need of treatment as well 
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as increase the hope and expectations regarding the po-
tential effects of treatment. 
 A third finding in this study was that parents of short 
SGA children had high expectations regarding not only 
the growth promoting effects, but also the psychological 
effects of GH therapy: 81% of the parents expected an im-
provement how the child feels, predominantly an in-
crease of self-confidence and an improvement of self-es-
teem. As far as we know, the parental expectations re-
garding potential psychological effects of GH treatment 
have not been studied. The parental expectations of an 
improved well-being could probably be understood 
against the background of the general assumption in 
Western society that short stature is socially disadvanta-
geous  [21, 24, 25] . Moreover, the expected catch-up 
growth induced by GH treatment could result in a stature 
more in accordance with chronological age as well as in 
a decrease in the height difference compared to peers, re-
sulting in a better psychosocial adaptation.
 Of note, despite the expectations of improved well-be-
ing, the perspective of GH treatment also induced fears 
in half of the parents at the start of therapy, mainly be-
cause of painfulness of injections and potential side ef-
fects. Parents were obviously more concerned about side 
effects in girls than in boys. Several studies provide evi-
dence replicating the societal bias that taller stature is 
more important in boys than in girls  [26] . As a conse-
quence, parents might be less tolerant of potential side 
effects and constraints associated with GH treatment, 
and less ready to take risks in girls than in boys. Parents 
were also more concerned about side effects in children 
with less growth retardation. A similar reasoning could 
be applied, i.e. parents probably are more sceptical about 
treatment if the need is less.  Fear of side effects and pain-
fulness of injections were more present in mothers with 
a higher socio-economic status. We hypothesize that 
mothers with a higher socio-economic status probably 
question their doctor more about the potential con-
straints of GH treatment, and tend to obtain complemen-
tary information or a second opinion by other ways, such 
as the internet or their private network of relations.
 After 2 years, fewer parents and children were con-
cerned by short stature, in the GH-treated as well as in 
the untreated group. These findings are in line with the 
only 2 studies published up to now, evaluating the chil-
dren’s attitudes and emotional adjustment to shortness 
during GH therapy and demonstrating that GH treat-
ment had a beneficial effect on children’s attitudes to be-
ing short  [10, 11] . The improvement of psychological well-
being as reported by half of the parents of treated as well 
as untreated children after 2 years, irrespective of current 
height and/or growth status, is partially in line with the 
findings of other studies in short normal children dem-
onstrating a lack of difference in self-esteem and quality 
of life between GH-treated and untreated children  [27, 
28] . The improvement in well-being could be due to an 
attention effect: the feeling of greater emotional support 
as well as of attention paid to the problem of short stature 
by the parents and medical team, leading to a reduction 
of emotional distress associated with short stature.  The 
perspective of treatment after 2 years of follow-up might 
have been a bias for the evaluation of the untreated 
group. 
 With respect to social contact, a considerable number 
of parents reported teasing by peers because of short stat-
ure at the start of the study. In line with the findings of 
Tanaka et al.  [11] in GH-treated SGA children a decline 
was observed after 2 years of GH therapy. Several authors 
published convincing evidence that short stature is an 
important factor in interactions with peers, children with 
significantly short stature being more vulnerable to di-
verse developmental, social and educational problems 
 [22, 24, 25, 29–32] . Some critical studies stressed the risk 
of inappropriately attributing problems of behavioural 
and emotional adjustment exclusively to short stature 
and, depending on the author, diverse factors were put 
forward as crucial determinants of behavioural and emo-
tional problems such as social class  [33] , cognitive abili-
ties  [21] , the underlying medical condition  [34] , and re-
ferral to clinic because of short stature  [35] . Undoubtedly, 
catch-up growth in children with short stature might 
positively influence the social interactions directly 
through the positive reactions about the obvious growth 
by peers and adults, and indirectly by enhancing the 
child’s self-esteem and the way the child likes himself, as 
well as by being treated more according to his chrono-
logical age  [32] . Our findings of a positive impact of GH 
treatment on emotional and social functioning are in line 
with the findings of other studies in children with short 
stature due to other reasons than intra-uterine growth 
retardation  [23, 36, 37] . Up to now, few studies have been 
published on the psychological effects of GH treatment 
in SGA children  [11, 38, 39] . Van der Reijden-Lakeman et 
al.  [38] demonstrated a beneficial effect on attention ca-
pacity, and a significant increase in general self-esteem 
and social acceptance after 2 years of GH therapy. Van 
Pareren et al.  [39] reported a significant improvement of 
behaviour and self-perception after long-term GH treat-
ment. 
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 In our study, satisfaction with GH therapy was high, 
with respect to both growth promoting effects and psy-
chological tolerance. Parental initial fears for side effects 
and painfulness of injections disappeared almost com-
pletely once GH treatment was started and compliance, 
as reported by the parents, was very good. Although the 
injections caused problems in half of the families during 
the first weeks, they subsequently became a habit for the 
majority of children. After 2 years, GH treatment was ex-
perienced more positively by the parents than by the chil-
dren themselves. Moreover, parents tended to underesti-
mate the burden for the child, since the parents thought 
that the injections were not painful anymore after 2 years, 
whereas for two thirds of the children the injections were 
still somewhat painful. Tanaka  [11] reported similar ob-
servations in GH-treated SGA children but a less positive 
evaluation in parents, i.e. discomfort during GH treat-
ment was experienced by one third of the children and 
parents.
 Some caution is needed in the interpretation of the re-
sults of our study. Despite an inclusion period of 1½ years, 
and a nation wide recruitment, only a limited number of 
patients could be recruited for this study, limiting its sta-
tistical power, especially in the subgroup analysis. The 
subgroup analysis should be treated with scepticism ir-
respective of its statistical significance. Another weak-
ness of our study design is that most of the studied pa-
tients were referred to a university hospital. Pre-referral 
counselling, which was not studied by us, might have in-
fluenced the concerns and expectations of the parents, 
despite the fact that in each centre an equal number of 
untreated and treated subjects was obtained by including 
the centre in the stratified randomization. Moreover, the 
perspective of GH treatment after 2 years of follow-up of 
the untreated group could have been a bias and as such 
weakened the strength of having a control group. Because 
this trial was not conducted double-blind, we cannot ex-
clude the Hawthorne effect (the phenomenon that sub-
jects, when observed in a study, temporarily change their 
behaviour or performance), as a major bias, despite the 
fact that the analysis was performed after 2 years. Due to 
the young age of the study group several answers are lack-
ing in the children’s reporting, and we were forced to rely 
mainly upon the parents’ reporting. Also, no strict com-
pliance monitoring was performed in our study and the 
results depend on the parents’ reporting, although the 
growth response in the treated children was always above 
the growth increment found in untreated patients. An-
other potential weakness is that preterm SGA children 
with a gestational age below 34 weeks, who might present 
a considerable part of short SGA infants proposed for GH 
therapy in daily clinical practice, were not studied by us. 
However, preterm short SGA children present a different 
postnatal growth pattern, and have other morbidities 
during infancy and childhood than term short SGA chil-
dren do. We cannot exclude that concerns, expectations 
and perceptions regarding stature, physical appearance 
and psychosocial functioning might be different in this 
specific population. 
 In conclusion, the majority of parents were concerned 
about the short stature of their SGA child, and the per-
spective of GH treatment induced major adult height ex-
pectations. Parental concerns about short stature were 
related neither to the health and developmental status of 
the child nor to the maternal auxological or demograph-
ic parameters, whereas adult height expectations were re-
lated to the child’s birth weight and developmental status. 
Before the start of GH treatment, fears about side effects 
and painfulness of injections were present in half of the 
parents. Once GH treatment was started, concerns about 
short stature and fears about GH treatment decreased. 
Improvement of how the child feels was observed in half 
of both treated and untreated children, irrespective of 
their change in height. Changes in physical appearance 
were obvious for treated children and their parents. Chil-
dren and parents reported that GH injections were phys-
ically and emotionally rather well tolerated.
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